Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma
- 1 February 1985
- journal article
- research article
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 99 (6) , 567-572
- https://doi.org/10.1017/s0022215100097255
Abstract
A total of 137 patients with biopsy-proved anaplastic epidermoid nasopharyngeal carcinoma (NPC) seen at the National Taiwan University Hospital from December 1971 through December 1973, were studied serologically before radiotherapy and during the follow-up period up to December 1982. A clear control study on 134 healthy patients or patients with diseases other than NPC was also done. EB virus-associated anti-VCA antibodies in both IgG and IgA classes were titrated by means of indirect immunofluorescent antibody method on two to six samples of serum from the patients during the follow-up study. When seropositive standard was set at 1:640 for anti-VCA IgG and 1:40 for anti-VCA IgA, the seropositive rates were 63.5 per cent and 81.1 per cent for NPC patients before treatment and 2.9 per cent and 2.2 per cent for the control respectively. The differences of seropositive rates between the patients and control were statistically highly significant, as .chi. 2 > 111, P < 0.0005. At the completion of radiotherapy and during the following year, some reduction and fluctuation of seropositive rates were seen in both cured and recurrent patients. From the second year after radiotherapy and thereafter, the seropositive rates were 72 per cent-100 per cent for patients with recurrences and 17.6 per cent - 30.8 per cent for cured patients. The differences were significant (.chi. 2 > 24.8, P < 0.0005). Therefore, high titers of anti-VCA antibodies may coexist with cancer tissue in NPC patients, IgA class antibodies is slightly higher in sensitivity. In patients with high titers of antibodies after radiotherapy, detailed examination should be done for the detection of possible recurrence or metastasis with a close follow-up.This publication has 10 references indexed in Scilit:
- Application of Epstein‐Barr Virus Serology to the Diagnosis and Staging of North American Patients with Nasopharyngeal CarcinomaOtolaryngology -- Head and Neck Surgery, 1983
- IgA antibody, antibody‐dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinomaInternational Journal of Cancer, 1981
- Dynamics of Epstein-Barr virus antibody titre in nasopharyngeal carcinomaComparative Immunology, Microbiology and Infectious Diseases, 1979
- Epstein-Barr Virus-Associated Antigens in Nasopharyngeal Carcinoma: Relation to Clinical Course of American PatientsJAMA Otolaryngology–Head & Neck Surgery, 1978
- Prognosis of Nasopharyngeal Carcinoma by Epstein-Barr Virus Antibody TiterJAMA Otolaryngology–Head & Neck Surgery, 1977
- Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinomaInternational Journal of Cancer, 1976
- Comparison of the anti‐ebv titer and the ebv‐associated membrane reactive and precipitating antibody levels in the sera of burkitt lymphoma and nasopharyngeal carcinoma patients and controlsInternational Journal of Cancer, 1970
- Immunofluorescence and Herpes-Type Virus Particles in the P3HR-1 Burkitt Lymphoma Cell LineJournal of Virology, 1967
- PRECIPITATING ANTIBODY IN HUMAN SERUM TO AN ANTIGEN PRESENT IN CULTURED BURKITT'S LYMPHOMA CELLSProceedings of the National Academy of Sciences, 1966